Bexarotene and Hypopituitarism
ABSTRACT: Objective: Bexarotene is currently approved for treatment of cutaneous T-cell lymphoma and is also under investigation for other cancers such as lung, breast, and thyroid cancer. We recently reported a patient with mycosis fungoides treated with bexarotene. The treatment induced hypopituit...
Main Authors: | Hulusi Atmaca, MD, Gülşen Işıklı, MD, Nilgün Sentürk, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-01-01
|
Series: | AACE Clinical Case Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060520302522 |
Similar Items
-
A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
by: Shuyue Ren, et al.
Published: (2020-09-01) -
Preclinical PET Neuroimaging of [C]Bexarotene
by: Benjamin H. Rotstein PhD, et al.
Published: (2016-08-01) -
Photodegradation of Bexarotene and Its Implication for Cytotoxicity
by: Agata Kryczyk-Poprawa, et al.
Published: (2021-08-01) -
Triggering of Suicidal Erythrocyte Death by Bexarotene
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2016-12-01) -
Effect of Bexarotene on Platelet Activation and Apoptosis
by: Hang Cao, et al.
Published: (2017-06-01)